APA (7th ed.) Citation

RASLOVA, K., DOBIASOVA, M., NAGYOVA, A., FABRY, R., RAUCHOVA, H., & DUSINSKA, M. (1998). Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: Effects on HDL quality, LDL susceptibility to oxidation and DNA damage. European journal of clinical pharmacology, 54(9-10), 697-699. https://doi.org/10.1007/s002280050537

Chicago Style (17th ed.) Citation

RASLOVA, K., M. DOBIASOVA, A. NAGYOVA, R. FABRY, H. RAUCHOVA, and M. DUSINSKA. "Ciprofibrate Treatment in Patients with Atherogenic Lipoprotein Phenotype: Effects on HDL Quality, LDL Susceptibility to Oxidation and DNA Damage." European Journal of Clinical Pharmacology 54, no. 9-10 (1998): 697-699. https://doi.org/10.1007/s002280050537.

MLA (9th ed.) Citation

RASLOVA, K., et al. "Ciprofibrate Treatment in Patients with Atherogenic Lipoprotein Phenotype: Effects on HDL Quality, LDL Susceptibility to Oxidation and DNA Damage." European Journal of Clinical Pharmacology, vol. 54, no. 9-10, 1998, pp. 697-699, https://doi.org/10.1007/s002280050537.